Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/genuine-biotech-limited" target="_blank" data-smartkarma-citation="entities:36220:1" rel="noopener">Genuine Biotech (GBL HK)</a> has filed for HK listing. Its Azvudine received NMPA approval for the treatment of COVID-19 in July 2022 to become the first China-made oral COVID-19 drug.</li>
<li>Azvudine was conditionally approved by the NMPA for the treatment of HIV infection in July 2021. However, the drug is yet to be commercialized.</li>
<li>Genuine Biotech plans to use the IPO proceeds for the commercialization of Azvudine. The company’s current cash balance can maintain its financial viability for approximately 20 months.</li>
</ul>



Genuine Biotech (GBL HK) has filed for HK listing. Its Azvudine received NMPA approval for the treatment of COVID-19 in July 2022 to become the first China-made oral COVID-19 drug.
Azvudine was conditionally approved by the NMPA for the treatment of HIV infection in July 2021. However, the drug is yet to be commercialized.
Genuine Biotech plans to use the IPO proceeds for the commercialization of Azvudine. The company’s current cash balance can maintain its financial viability for approximately 20 months.


Genuine Biotech (GBL HK): COVID Pill No Longer Attractive Opportunity; Thin Pipeline Mars Conviction

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Biocytogen Pharmaceuticals (Beijing) / Equity Capital Markets

<ul>
<li>Biocytogen raised HKD 471m (USD 60.77m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, September 1st.</li>
<li>In the previous note, we looked at the company's business lines including biotech and animal model businesses.</li>
<li>In this note, we provide an update for the IPO before trading debut.</li>
</ul>


Biocytogen raised HKD 471m (USD 60.77m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, September 1st.
In the previous note, we looked at the company's business lines including biotech and animal model businesses.
In this note, we provide an update for the IPO before trading debut.


Biocytogen (百奥赛图) IPO Trading: Week Demand

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

China Tourism Group Duty Free / Equity Capital Markets

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.</li>
<li>On the IPO front, China Tourism's listing appears to have set the ball rolling for others to follow.</li>
<li>After a flurry of activity in the prior week, there weren't any major placements this week.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
On the IPO front, China Tourism's listing appears to have set the ball rolling for others to follow.
After a flurry of activity in the prior week, there weren't any major placements this week.


ECM Weekly (28th Aug 2022) - China Tourism, BA REIT, Hongjiu Fruit, YH Ent, Biocyto, WM, APM, Daiwa

<ul>
<li>Biocytogen is a leading animal model player in China expanding into biotech. The company launched a downsized deal to  raise up to USD 70m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company business lines and compared the company's operation with leading animal model players.</li>
<li>In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.</li>
</ul>


Biocytogen is a leading animal model player in China expanding into biotech. The company launched a downsized deal to  raise up to USD 70m via a Hong Kong listing.
In our previous note, we looked at the company business lines and compared the company's operation with leading animal model players.
In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.


Biocytogen (百奥赛图) IPO: Short Term and Long Term Challenges

Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/biocytogen-pharmaceuticals-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:34533:1" rel="noopener">Biocytogen Pharmaceuticals (Beijing) (BCP HK)</a> is a biopharmaceutical and pre-clinical research services company with two core products (YH003 and YH001) and 10 other pipeline candidates.</li>
<li>The company currently does not have any commercialised products and earns revenue through offering pre-clinical research services and antibody development.</li>
<li>Biocytogen’s business model comes with inherent risks such as absence of approved drugs. Hence, we would recommend staying on the side line.</li>
</ul>



Biocytogen Pharmaceuticals (Beijing) (BCP HK) is a biopharmaceutical and pre-clinical research services company with two core products (YH003 and YH001) and 10 other pipeline candidates.
The company currently does not have any commercialised products and earns revenue through offering pre-clinical research services and antibody development.
Biocytogen’s business model comes with inherent risks such as absence of approved drugs. Hence, we would recommend staying on the side line.


Biocytogen Pharma IPO: Large Drug Pipeline but Negatives Outweighs the Positives

China

Biocytogen Pharmaceuticals Beijing Co., Ltd. operates as a biopharmaceutical and revenue generating pre clinical research services company. The Company produces mmunoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. Biocytogen Pharmaceuticals Beijing provides drug development, therapeutic antibody discovery and development, and other services.

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

Genuine Biotech (GBL HK): COVID Pill No Longer Attractive Opportunity; Thin Pipeline Mars Conviction

Genuine Biotech has filed for Hong Kong listing to raise funds to commercialize its newly approved drug. The company’s Azvudine is the first China...

Tina Banerjee

Biocytogen (百奥赛图) IPO Trading: Week Demand

We provide an update for Biocytogen's listing tmr. Demands are weak while valuation is rich. We don't expect an upside on debut.

Ke Yan, CFA, FRM

ECM Weekly (28th Aug 2022) - China Tourism, BA REIT, Hongjiu Fruit, YH Ent, Biocyto, WM, APM, Daiwa

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Biocytogen (百奥赛图) IPO: Short Term and Long Term Challenges

Biocytogen launched a downsized deal. We look at the deal terms, dynamics and provided an updated thought on the deal. We think the company's...

Ke Yan, CFA, FRM

Biocytogen Pharma IPO: Large Drug Pipeline but Negatives Outweighs the Positives

Biocytogen doesn't have any products approved and are in early stages of development. Some competing drugs are in advanced phases. Pre-clinical...

Shifara Samsudeen, FCMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)